Asker Healthcare Group AB is a Swedish company focused on providing medical products and solutions across Europe. Founded in 2006 and headquartered in Danderyd, Sweden, the company offers a diverse range of medical supplies, devices, and equipment, including surgical and diagnostic instruments, urology and ultrasound products, operating room equipment, hygiene items, beauty clinic products, defibrillators, wound care supplies, veterinary equipment, and mobility aids. Asker also develops disposable medical supplies marketed under the Evercare, Selefa, and Embra brands and supplies educational products for assistive technology centers. Operational in 19 countries, Asker Healthcare Group has a presence in Sweden, Norway, Finland, the Baltic countries, Netherlands, Belgium, Luxembourg, Denmark, the UK, Ireland, Germany, Austria, Switzerland, France, Slovakia, Czech Republic, and Poland. As of August 2026, the company employs approximately 4,885 people. The firm went public on Nasdaq Stockholm in March 2025, pricing shares at SEK 70, which valued the company at around SEK 26.8 billion. In November 2025, Asker acquired Swiss company Innomedicus, which had a turnover of about SEK 50 million in 2024. Asker's mission centers on improving patient outcomes, reducing healthcare costs, and ensuring a sustainable value chain in the healthcare sector.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Asker Healthcare Group AB's offering is currently approved on OTHER. Asker Healthcare Group AB is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Asker Healthcare Group AB.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/asker-healthcare-group-ab" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Asker Healthcare Group AB — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/asker-healthcare-group-ab?theme=light as the src instead.
https://www.discoveripo.com/ipo/asker-healthcare-group-ab/opengraph-image
Asker Healthcare Group AB IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/asker-healthcare-group-ab?utm_source=embed&utm_medium=text&utm_campaign=asker-healthcare-group-ab
Get emailed when Asker Healthcare Group AB's terms, price, or expected date change — no weekly noise, just this company.
Asker Healthcare Group AB is listing on OTHER.
Asker Healthcare Group AB is a Swedish company focused on providing medical products and solutions across Europe. Founded in 2006 and headquartered in Danderyd, Sweden, the company offers a diverse range of medical supplies, devices, and equipment, including surgical and diagnostic instruments, urology and ultrasound products, operating room equipment, hygiene items, beauty clinic products, defibrillators, wound care supplies, veterinary equipment, and mobility aids. Asker also develops disposable medical supplies marketed under the Evercare, Selefa, and Embra brands and supplies educational products for assistive technology centers. Operational in 19 countries, Asker Healthcare Group has a presence in Sweden, Norway, Finland, the Baltic countries, Netherlands, Belgium, Luxembourg, Denmark, the UK, Ireland, Germany, Austria, Switzerland, France, Slovakia, Czech Republic, and Poland. As of August 2026, the company employs approximately 4,885 people. The firm went public on Nasdaq Stockholm in March 2025, pricing shares at SEK 70, which valued the company at around SEK 26.8 billion. In November 2025, Asker acquired Swiss company Innomedicus, which had a turnover of about SEK 50 million in 2024. Asker's mission centers on improving patient outcomes, reducing healthcare costs, and ensuring a sustainable value chain in the healthcare sector.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy